29
Participants
Start Date
December 31, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
transfusion of 5×10^8 PD-1 knockout TILs per kg body weight
Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
transfusion of 1×10^9 PD-1 edited TILs per kg body weight
Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
transfusion of 2×10^9 PD-1 edited TILs per kg body weight
Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
transfusion of maximum dose without side effects among group A, B and C
Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
RECRUITING
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Ruijin Hospital
OTHER